請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16521
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳建仁,蕭朱杏 | |
dc.contributor.author | Kai-Hsiang You | en |
dc.contributor.author | 游凱翔 | zh_TW |
dc.date.accessioned | 2021-06-07T18:18:53Z | - |
dc.date.copyright | 2012-03-02 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-02-02 | |
dc.identifier.citation | 1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500.
2. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56. 3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-41. 4. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009;29 Suppl 1:100-7. 5. Rapicetta M, Ferrari C, Levrero M. Viral determinants and host immune responses in the pathogenesis of HBV infection. J Med Virol 2002;67:454-7. 6. Zhang X, Zhang W, Ye L. Pathogenesis of hepatitis B virus infection. Future Virol. 2006;1:637-47. 7. Liu CJ, Cheng HR, Chen CL, Chen TC, Tseng TC, Wang ZL, Chen PJ, Liu CH, Chen DS, Kao JH. Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C. J Viral Hepat 2011;18:e482-90. 8. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WEt, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-8. 9. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010;52:1232-41. 10. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007;5:1462-8. 11. Volz T, Lutgehetmann M, Wachtler P, Jacob A, Quaas A, Murray JM, Dandri M, Petersen J. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007;133:843-52. 12. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004;24 Suppl 1:3-10. 13. Blumberg BS, Alter HJ, Visnich S. A 'NEW' ANTIGEN IN LEUKEMIA SERA. JAMA 1965;191:541-6. 14. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2. 15. Brunetto MR. A new role for an old marker, HBsAg. J Hepatol 2010;52:475-7. 16. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, You SL, Iloeje UH, Chen CJ. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010;139:474-82. 17. Moucari R, Marcellin P. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. Liver Int 2011;31 Suppl 1:122-8. 18. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007;45:1187-92. 19. Kim JH, Lee JH, Park SJ, Bae MH, Kim do Y, Kim JK, Choi MS, Koh KC, Paik SW, Yoo BC. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study. Hepatogastroenterology 2008;55:578-81. 20. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34:139-45. 21. Gerlich W, Thomssen R. Standardized detection of hepatitis B surface antigen: determination of its serum concentration in weight units per volume. Dev Biol Stand 1975;30:78-87. 22. Petrilli FL, Crovari P, De Flora S. Quantitative detection and typing of HBs Ag and anti-HBs by radioimmunoassay techniques. Dev Biol Stand 1975;30:103-110. 23. Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int 2009. 24. Wursthorn K, Jaroszewicz J, Zacher BJ, Darnedde M, Raupach R, Mederacke I, Cornberg M, Manns MP, Wedemeyer H. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 2011;50:292-6. 25. Zacher BJ, Moriconi F, Bowden S, Hammond R, Louisirirotchanakul S, Phisalprapa P, Tanwandee T, Wursthorn K, Brunetto MR, Wedemeyer H, Bonino F. Multicenter evaluation of the elecsys hepatitis B surface antigen quantitative assay. Clin Vaccine Immunol 2011;18:1943-50. 26. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, Romagnoli V, Cherubini B, Moscato G, Maina AM, Cavallone D, Bonino F. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010;139:483-90. 27. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011;55:1121-31. 28. Jang JW, Yoo SH, Kwon JH, You CR, Lee S, Lee JH, Chung KW. Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection. Aliment Pharmacol Ther 2011;34:1337-46. 29. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, Flisiak R, Bock CT, Manns MP, Wedemeyer H, Cornberg M. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010;52:514-22. 30. Kim YJ, Cho HC, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW. The change of the quantitative HBsAg level during the natural course of chronic hepatitis B. Liver Int 2011;31:817-23. 31. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011;54:E1-9. 32. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, Levy M, Locarnini SA. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010;52:508-13. 33. Sonneveld MJ, Zoutendijk R, Janssen HL. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat 2011;18:449-57. 34. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, Lau GK, Lewin SR, Visvanathan K, Desmond PV, Locarnini SA. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51:1933-44. 35. Togo S, Arai M, Tawada A, Chiba T, Kanda T, Fujiwara K, Imazeki F, Yokosuka O. Clinical importance of serum hepatitis B surface antigen levels in chronic hepatitis B. J Viral Hepat 2011;18:e508-15. 36. Antaki N, Zeidane N, Alhaj N, Hadad M, Baroudi O, Antaki F, Abouharb R, Haffar S, Abdelwahab J, Alideeb S, Asaad F, Aljesri A, Doghman D, Aaraj R, Ibrahim N, Ali A, Assil M, Sabah H, Katranji N, Kebbewar K. HBsAg titers in the different phases of hepatitis B infection in Syrian patients. J Clin Virol 2011. 37. Su TH, Hsu CS, Chen CL, Liu CH, Huang YW, Tseng TC, Liu CJ, Chen PJ, Lai MY, Chen DS, Kao JH. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther 2010;15:1133-9. 38. Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS, Kao JH. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011;141:517-25, 525 e1-2. 39. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Determinants of spontaneous surface antigen loss in HBeAg-negative patients with a low viral load. Hepatology 2011. 40. Chen YC, Jeng WJ, Chu CM, Liaw YF. Decreasing Levels of HBsAg Predict HBsAg Seroclearance in Patients With Inactive Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2011. 41. Lee JM, Ahn SH, Kim HS, Park H, Chang HY, Kim do Y, Hwang SG, Rim KS, Chon CY, Han KH, Park JY. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011;53:1486-93. 42. Ma H, Yang RF, Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J Gastroenterol Hepatol 2010;25:1498-506. 43. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251-7. 44. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol 2011;26 Suppl 1:123-30. 45. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002;83:2059-73. 46. Norder H, Hammas B, Lofdahl S, Courouce AM, Magnius LO. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol 1992;73 ( Pt 5):1201-8. 47. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-9. 48. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010;15:133-43. 49. Kao JH, Chen PJ, Lai MY, Chen DS. Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C. J Clin Microbiol 2002;40:22-5. 50. Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004;39:1694-701. 51. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134-43. 52. Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, Gish RG, Kramvis A, Shimada T, Izumi N, Kaito M, Miyakawa Y, Mizokami M. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006;44:915-24. 53. Bartholomeusz A, Locarnini S. Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype. Hepatology 2001;34:432-5. 54. Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999;52:25-137. 55. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2:588-91. 56. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, Miyakawa Y, Mayumi M. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994;68:8102-10. 57. Gunther S, Piwon N, Will H. Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653) --> T, A(1762) --> T and G(1764) --> A mutations in the core promoter. J Gen Virol 1998;79 ( Pt 2):375-80. 58. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31:1037-44. 59. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2010;26:628-38. 60. Chen YL, Chen PJ, Yang HI, Chen CJ. Risk of liver cirrhosis associated with genotypes and mutants of hepatitis B virus [Abstract]. J. Hepatol. 2007;45:222. 61. Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, Huang WL, Lu SF, Jih J, Chen DS, Chen PJ. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004;41:659-66. 62. Park H, Lee JM, Seo JH, Kim HS, Ahn SH, Kim DY, Han KH, Chon CY, Park JY. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers. Liver Int 2011. 63. Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, Chen CJ. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 2001;93:1644-51. 64. Miyakawa Y, Okamoto H, Mayumi M. The molecular basis of hepatitis B e antigen (HBeAg)-negative infections. J Viral Hepat 1997;4:1-8. 65. Takahashi K, Aoyama K, Ohno N, Iwata K, Akahane Y, Baba K, Yoshizawa H, Mishiro S. The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol 1995;76 ( Pt 12):3159-64. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16521 | - |
dc.description.abstract | 背景及目標:近年來血清中HBsAg濃度可反應慢性B型肝炎患者的疾病自然史及預測抗病毒藥物治療反應。血清中HBsAg的產生可能會受到病毒與宿主間交互作用影響,到目前為止,HBV的基因型及突變株對於HBsAg濃度的影響仍不太清楚。本研究主要評估HBV的基因型、前核心區及基礎核心促進子之突變對於HBsAg濃度的影響。方法:資料來自1991年到1992年間收集的社區世代研究,共計2,312名無肝癌既往史之個案參加。在基線收集個案的血液,基因型測定是利用melting curve analysis,而使用羅氏Elecsys HBsAg II Quant assay定量HBsAg濃度。另外共計1,440名個案血清中HBV DNA濃度大於104 copies/mL,利用direct sequencing測量前核心區及基礎核心促進子之突變。利用線性回歸或羅吉斯回歸再調整相關干擾因素後,找出影響血清中HBsAg濃度因素。結果:在個案血清中HBV DNA濃度大於104 copies/mL為研究對象的多變量迴歸分析中,基因型C相較於基因型B有較高的HBsAg濃度(β=0.43, SE=0.04, p<0.0001);前核心區的Mutant type相較於Wild type有較低的HBsAg濃度(β=-0.26, SE=0.05, p<0.0001);基礎核心促進子的mutant type相較於wild type有較低的HBsAg濃度(β=-0.22, SE=0.05, p<0.0001)。而基因型C相較於基因型B在兩組dataset都與較高的HBsAg濃度有關。在結合了基因型、前核心區及基礎核心促進子,結果發現,當基因型C、前核心區及基礎核心促進子為Wild type相較於基因型B、前核心區及基礎核心促進子為Wild type有較高的HBsAg濃度(β=0.65, SE=0.11, p<0.0001)。結論:HBV的基因型、前核心區及基礎核心促進子的突變與HBsAg濃度有關,基因型C對於血清中HBsAg濃度是高於基因型B,而前核心區及基礎核心促進子的Mutant type對於血清中HBsAg濃度是低於Wild type。 | zh_TW |
dc.description.abstract | Background & Aims: Qualitative Hepatitis B surface antigen (HBsAg) is becoming an innovative concept that information on HBsAg levels can address the natural history of the disease and predict treatment response in chronic hepatitis B (CHB). The production of HBsAg may change during the virus-host interaction in CHB. The impact of HBV genotype and hotspot mutants on HBsAg production remains unclear. This study aimed to evaluate the effects of HBV genotype and precore and basal core promoter mutations on the expression of HBsAg. Methods: A total of 2,312 individuals with CHB infection were enrolled between 1991 and 1992 in this community-based study. Serum samples collected at baseline were tested for genotype by melting curve analysis and HBsAg levels at study entry were quantified using the Roche Elecsys HBsAg II Quant assay. Participants who had a baseline serum HBV DNA level greater than 104 copies/mL (n=1,440) were tested for precore G1896A and BCP A1762T/G1764A mutants by direct sequencing. Multiple regression analyses were performed to identify the independent factors affecting serum HBsAg titers. Results: Among participants with a baseline HBV DNA level of 104 copies/mL or greater, the multivariable-adjusted beta coefficient of the expression of HBsAg was 0.43 (SE=0.06) for genotype C versus genotype B, -0.26 (SE-0.05) for precore mutant type versus wild type, -0.22 (SE=0.05) for BCP mutant type versus wild type. as associated with a higher HBsAg expression than infection with genotype B for both dataset analyses. HBsAg titers were lowest among participants infected with genotype C HBV and mutant type for precore 1896 variant and mutant type for the BCP 1762/1764 variant (beta coefficient=-0.75, SE-0.08, p<0.0001). Conclusions: HBV genotype and precore and BCP mutants are correlated with the expression of HBsAg titers. Effect of genotype C on the expression of HBsAg was higher than genotype B and effects of precore and BCP mutants on the expression of HBsAg were lower than wild type. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T18:18:53Z (GMT). No. of bitstreams: 1 ntu-101-R97842015-1.pdf: 827261 bytes, checksum: 2e3ad72473823d8037a65aa845e8dc27 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 致謝 i
摘要 ii ABSTRACT iii LIST OF FIGURES vi LIST OF TABLES vii INTRODUCTION 1 Hepatitis B Surface Antigen and Quantification 1 HBV Genotypes 3 HBV Mutants 5 Specific Aims 6 METHODS 8 Cohort Enrollment and Subject Flow 8 Interview and Blood Collection 9 Laboratory Analysis 9 Data Analysis 11 RESULTS 13 DISCUSSION 19 REFERENCES 24 | |
dc.language.iso | en | |
dc.title | 感染不同B型肝炎病毒基因型及突變株對血清中B型肝炎病毒表面抗原濃度之相關性研究 | zh_TW |
dc.title | Hepatitis B Virus Genotype and Mutants associated with the Expression of Hepatitis B Surface Antigen in Serum | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 于明暉,楊懷壹 | |
dc.subject.keyword | B型肝炎病毒,B型肝炎病毒表面抗原,基因型,突變株,前核心區,基礎核心促進子, | zh_TW |
dc.subject.keyword | Hepatitis B Virus,Hepatitis B Surface Antigen,HBV Genotype,HBV Mutants,Precore,Basal Core Promoter, | en |
dc.relation.page | 56 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2012-02-02 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 807.87 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。